Nasdaq suspends Acusphere's shares on trial review
This article was originally published in Scrip
Executive Summary
Nasdaq has halted trading in Acusphere's shares while the US FDA meets publicly to review the company's coronary artery disease detection drug, Imagify (perflubutane polymer microspheres).